Aldehyde dehydrogenase 2 Glu504Lys variant predicts a worse prognosis of acute coronary syndrome patients. Issue 4 (14th February 2018)

• Record Type: Journal Article
• Authors: Pan, Chang; Zhao, Yu; Bian, Yuan; Shang, Rui; Wang, Jia‐li; Xue, Li; Wei, Shu‐jian; Zhang, He; Chen, Yu‐guo; Xu, Feng
• Is Part Of: Journal of cellular and molecular medicine. Volume 22:Issue 4(2018)
• Page Start: 2518
• Page End: 2522
• Publication Date: 2018-02-14
• Subjects: acute coronary syndrome -- aldehyde dehydrogenase 2 -- Glu504Lys variant -- prognosis; Cytology; Medicine; Molecular Biology; Cytologie -- Périodiques; Médecine -- Périodiques; Biologie moléculaire -- Périodiques; Cytology -- Periodicals; Medicine -- Periodicals; Molecular biology -- Periodicals; 611.01805
• DOI: 10.1111/jcmm.13536
• Languages: English
• ISSNs: 1582-1838

Abstract

Abstract: Aldehyde dehydrogenase 2 (ALDH2) Glu504Lys variant was an independent risk factor for acute coronary syndrome (ACS). However, there are lacking researches about the relationship between the variant and prognosis of ACS. In the prospective study, 377 ACS patients were grouped into the wild‐type (*1/*1) and the mutation (*2/*2 + *1/*2) groups according to genotype detection. Compared with the wild‐type group, incidences of major adverse cardiac events (MACE) and cardiac death were both higher in the mutation group (9.2% vs 21.0%, P = .002; 5.2% vs 12.2%, P = .026); the MACE‐free and the cardiac‐death‐free cumulative survival rates were obviously lower in the mutation group. Moreover, the mutant genotypes were associated with significantly increased risk of MACE and cardiac death (HR 2.443, 95%CI: 1.390‐4.296, P = .002; HR 2.727, 95%CI: 1.303‐5.708, P = .008). These results suggested that ALDH2 Glu504Lys variant could predict a worse prognosis of ACS patients.